Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.59 |
| ▸ | BTK | Q06187 | 4/20 | 0.59 |
| ▸ | ITK | Q08881 | 5/20 | 0.59 |
| ▸ | SYK | P43405 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21109601 | 0.89 | EGFR (0.66) | EGFRBTKITKSYKMAPT | |
| SCHEMBL2348978 | 0.89 | ITK (0.62) | EGFRBTKITKSYKMAPT | |
| SCHEMBL21110438 | 0.87 | MAPT (0.49) | EGFRBTKITKSYKMAPT | |
| SCHEMBL21110443 | 0.87 | BTK (0.69) | EGFRBTKITKSYKMAPT | |
| SCHEMBL18012007 | 0.86 | SYK (0.63) | EGFRBTKITKSYK | |
| SCHEMBL14769135 | 0.85 | CNR2 (0.53) | EGFRBTKITKSYKMAPT | |
| SCHEMBL13498133 | 0.85 | EGFR (0.82) | EGFRBTKITK | |
| SCHEMBL13498134 | 0.85 | ITK (0.62) | EGFRBTKITKSYKMAPT | |
| SCHEMBL18011892 | 0.85 | SYK (0.66) | EGFRBTKITKSYK | |
| SCHEMBL12519750 | 0.85 | BTK (0.77) | EGFRBTKITKSYKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885ITK 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.